Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 358

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 358
---
 holders of Profusa are expected to be treated as dividend distributions and recorded in additional paid -incapital. The preliminary estimated aggregate fair value of Milestone Earnout Rights and Profusa Inducement Recoupment Earnout Rights is $9.6 million, which was determined using Monte Carlo Simulation approach. The Company estimated the vesting and payoff of the Milestone Earnout Shares and the Inducement Shares related to Milestone I Event and Milestone II Event for each simulated stock price path, and the vesting and payoff of the Milestone Earnout Shares related to Milestone III Event and Milestone IV Event for each simulated revenue path and the correlated stock price path. The fair value is then determined by averaging the payoff across all simulated paths and discounting it to the valuation date. All outstanding capital stock of Profusa will be converted into shares of common stock of Profusa, with the corresponding increase in the par value of common stock being recognized against additional paid -incapital. All outstanding junior convertible notes and senior convertible notes are expected to convert into the shares of New Profusa based on their respective conversion teams. Accordingly, no gain or loss is expected to be recognized upon conversion of the junior convertible notes and senior convertible notes. Outstanding vested and unvested share -basedawards of Profusa will be converted into the right to exercise such awards for common shares of New Profusa, adjusted proportionately based on the Exchange Ratio. Issuance of the Milestone Earnouts and Profusa Inducement Recoupment Earnouts to the holders of the vested in -the-moneyProfusa Options will represent a modification of the respective awards, however, the results of such modification is expected to be immaterial. Because no terms of all other share -basedawards are modified upon consummation 185 of the Business Combination, no accounting impact for such outstanding awards is expected. Public and private warrants of NorthView are not expected to be modified as a result of the Business Combination, resulting in no accounting impact upon consummation of Business Combination. Although the accounting treatment for the APAC Joint Venture has not yet been finalized as the transaction will not close prior to the completion of the Company’s merger, management has completed the accounting analysis and has concluded that this joint venture will be treated as an equity method investment. There are no liabilities expected to be transferred to the joint venture entity; however, Profusa will be contributing an irrevocable, exclusive, perpetual, sub -licensableand assignable license in Asia Pacific to use